Purpose: Cancer vaccines targeting tumor-associated antigens are being investigated for the therapy of tumors. Numerous strategies, including the direct intratumoral (i.t.) vaccination route, have been examined. For tumors expressing carcinoembryonic antigen (CEA) as a model tumorassociated antigen, we previously designed poxviral vectors that contain the transgenes for CEA and a triad of T-cell costimulatory molecules, B7-1, intercellular adhesion molecule-1, (ICAM-1), and leukocyte function associated antigen-3 (LFA-3) (CEA/TRICOM). Two types of poxvirus vectors were developed: replication-competent recombinant vaccinia and replication-defective recombinant fowlpox. We have shown previously that a vaccine regimen composed of priming mice s.c. with recombinant vaccinia-CEA/TRICOM and boosting i.t. with recombinant fowlpox-CEA/TRICOM was superior to priming and boosting vaccinations using the conventional s.c. route in inducing T-cell responses specific for CEA. These studies also showed that CEA was needed to be present both in the vaccine and in the tumor for therapeutic effects.
INTRODUCTION
Cancer vaccines are under investigation for the therapy of many types of cancers. Numerous strategies, including the route of vaccination, are being evaluated using a variety of vaccines (1 -8) .
We have previously described poxviral vectors that contain the transgenes for carcinoembryonic antigen (CEA) and a triad of T-cell costimulatory molecules, B7-1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function associated antigen-3 (LFA-3) (TRICOM) as well as vectors coexpressing the combination (CEA/TRICOM). Two types of poxvirus vectors were developed: replication-competent recombinant vaccinia (rV) and replication-defective recombinant fowlpox (rF; refs. 1, 9 -11). It has been shown that a diversified systemic prime and boost vaccine regimen, in which rV-CEA/TRICOM was used as a prime and rF-CEA/TRICOM as a boost, was more efficacious than continuous vaccination with rF-CEA/ TRICOM in the induction of CEA-specific T-cell responses and antitumor activity (9, 11) .
We have shown recently the advantage of an immunization regimen involving a s.c. prime vaccination with rV-CEA/ TRICOM followed by intratumoral (i.t.) boosting with rF-CEA/ TRICOM. These studies were done in CEA-transgenic mice, where CEA is a self-antigen (8) . This vaccine regimen was shown to be superior to s.c. priming followed by s.c. boosting. In addition, when wild-type viruses were used or when vaccines not encoding CEA (TRICOM) were used for either s.c. priming or i.t. boosting, tumor growth was not suppressed (8) . It is also important to note that this regimen was not effective on CEA À tumors. These studies showed the requirement of having the tumor-associated antigen (TAA) CEA both in the vaccine and in the tumor for the induction of the optimal antitumor activity as well as prime vaccination with rV virus and the addition of granulocyte macrophage colony-stimulating factor (GM-CSF). It was not known, however, what role, if any, other TAAs present in the target tumor played in the antitumor immune response.
We show here that in CEA + tumor-bearing CEAtransgenic mice vaccinated with the CEA/TRICOM s.c./i.t. regimen, T-cell immune responses could be detected not only to CEA encoded in vaccine vectors but also to other antigens expressed in the tumor: wild-type p53 and an endogenous retroviral epitope of gp70. Moreover, the magnitude of CD8 + T-cell immune responses to gp70 was far greater than that induced to CEA or p53. A majority of the T-cell population infiltrating the CEA + tumor after therapy were specific for gp70. These studies show the s.c./i.t. CEA/TRICOM vaccine regimen induces an antigen cascade, which in turn facilitates the regression of established tumors. These studies also underscore the need, in clinical vaccine studies, to examine host responses after vaccination not only to the antigen in the vaccine but also to other TAAs known to be associated with a given tumor type.
MATERIALS AND METHODS
Animals and Tumor Cells. Female C57BL/6 mice transgenic for human CEA (CEA-transgenic) were obtained from a breeding pair provided by Dr. John Thompson (Institute of Immunobiology, University of Freiburg, Freiburg, Germany). The generation and characterization of the CEAtransgenic mouse has been described previously (12, 13) . Mice were housed and maintained under pathogen-free conditions in microisolator cages until used for experiments at 6 to 8 weeks of age. The following tumor cell lines (H-2 b ) were used: lymphoma EL-4 cells, parental murine colon adenocarcinoma MC38 cells (14) Recombinant Poxvirus Vaccines. The rV and rF viruses containing the murine B7-1, ICAM-1, and LFA-3 genes (rV-TRICOM and rF-TRICOM, respectively) or in combination with the human CEA gene (rV-CEA/TRICOM and rF-CEA/TRI-COM, respectively) have been described (1, 2). The rF virus containing the gene for murine GM-CSF (rF-GM-CSF) has been described (16 Lymphocyte Proliferation Assay. To evaluate CD4 + Tcell responses specific for tumor antigens, splenic T cells were tested for proliferation in response to CEA protein as described previously (17) .
Cytotoxicity Assay. Using these recovered lymphocytes, tumor-killing activity was tested as described previously (17) . Briefly, the recovered lymphocytes, 51 Cr-labeled target cells (EL-4, 5 Â 10 3 per well), and each peptide were incubated for 5 hours (96-well U-bottomed plates), and radioactivity in supernatants was measured using a gamma counter (Corba Autogamma, Packard Instruments, Downers Grove, IL 51 Cr release in response to each control peptide was subtracted from that induced by the appropriate tumor antigen peptide. Data were averaged and graphed as D% F SD. Where mentioned in text, CTL activity was converted to lytic units as described previously (24) .
Cytokine Production Assay. The recovered lymphocytes separated as described above were also tested for cytokine production from CD8 + T cells in response to defined tumor antigen peptides. Recovered lymphocytes (5 Â 10 5 per well) were restimulated with fresh irradiated naive splenocytes as antigen-presenting cells (5 Â 10 6 per well) and with each peptide (10 Ag/mL CEA peptide, 2 Ag/mL p53 peptide, or 1 Ag/mL gp70 peptide). Twenty-four hours later, the supernatant fluid was collected and analyzed for murine cytokines using the Cytometric Bead Array kit (BD PharMingen, San Diego, CA). Nonspecific cytokine production in response to each control peptide was subtracted from that induced by the appropriate tumor antigen peptide.
Flow Cytometric Analysis. To analyze T-cell populations in mice treated with the CEA/TRICOM s.c./i.t. vaccination regimen, tumors were harvested and mechanically dispersed into single-cell suspensions. Peripheral blood was collected into 4% citrated PBS and removed RBC. The following antibodies were purchased from BD PharMingen and used for analysis: FITCconjugated anti-CD3e (hamster IgG1), CyChrome-conjugated Fig. 1A) . When mice were vaccinated s.c. with rV-CEA/ TRICOM on day 4 and then boosted s.c. with rF-CEA/TRICOM To determine if there was any antigen specificity to the antitumor responses noted above, CEA-transgenic mice were transplanted with parental (CEA À ) MC38 tumors. Control mice were vaccinated with PBS vehicle s.c. on day 4 and i.t. on days 11, 18, and 25 ( Fig. 1D ). When mice were vaccinated s.c. with rV-CEA/TRICOM on day 4 and then boosted s.c. with rF-CEA/TRICOM on days 11, 18, and 25, tumor growth was not significantly suppressed ( Fig. 1E) . Similarly, when mice were vaccinated s.c. with rV-CEA/TRICOM on day 4 and then boosted i.t. with rF-CEA/TRICOM on days 11, 18, and 25, tumor growth was not significantly suppressed ( Fig. 1F ; P = 0.27 compared with mice primed s.c. with rV-CEA/TRICOM and boosted s.c. with rF-CEA/TRICOM; Fig. 1E ). These results thus show that the CEA/TRICOM s.c. prime/i.t. boost regimen required CEA in the tumor for induction of antitumor activity.
Next, we attempted to treat larger tumors with the s.c. prime and i.t. boost vaccine regimen by withholding vaccine therapy until day 8 after tumor transplant. When therapy was initiated at this time, the mean tumor size was 51.2 F 16.7 mm 3 ( Fig. 1G-I ). Control mice were vaccinated with PBS s.c. on day 8 and i.t. on days 15, 22, and 29 ( Fig. 1G ). When mice were vaccinated s.c. with rV-CEA/TRICOM on day 8 and then boosted s.c. with rF-CEA/TRICOM on days 15, 22, and 29, no significant antitumor effects were noted compared with that of the control group ( Fig. 1H ; P = 0.08). When mice were vaccinated s.c. with rV-CEA/TRICOM on day 8 and then boosted i.t. with rF-CEA/TRICOM on days 15, 22, and 29, tumor growth was again significantly inhibited ( Fig. 1I ; P = 0.0001 compared with mice primed with rV-CEA/TRICOM s.c. and boosted with rF-CEA/TRICOM s.c.; Fig. 1H ). Finally, 5 of 10 mice in this group showed complete regression of tumors (Fig. 1I) . These results, taken together, show that s.c. priming followed by i.t. boosting is superior to s.c. priming followed by s.c. boosting.
CEA-Transgenic Mice Cured of CEA + + Tumors Reject Challenge with Diverse Tumor Types. To examine the extent of immunologic memory generated in mice cured by CEA/ TRICOM s.c. prime/i.t. boost vaccine therapy, eight CEAtransgenic mice cured after the therapy started on day 4 ( Fig.  1C) and five mice cured after the therapy started on day 8 ( Fig.  1I) were rechallenged with MC38-CEA + tumors (at day 60 after the first tumor transplantation). Nonvaccinated CEAtransgenic mice were transplanted with MC38-CEA + tumors at the same time as a control, and all mice developed progressive tumors. As shown in Table 1 , 100% of mice in the vaccinated group rejected the rechallenged MC38-CEA + tumors. Next, to further examine the specificity of the antitumor immunity to the CEA + tumors, these mice were challenged with parental (CEA À ) MC38 tumors 30 days after the rechallenge of MC38-CEA + tumors. The MC38 tumors were rejected in 92% (12 of 13) of mice cured by CEA/TRICOM s.c. prime/i.t. boost vaccine therapy (Table 1) . To determine if the antitumor immunity could translate to another tumor type, mice were challenged with syngeneic B16 melanoma cells 30 days after the challenge of parental MC38 tumors. None of these mice rejected the B16 tumors. However, tumor growth was significantly suppressed compared with that in the control mice (P = 0.0001; Table 1 ). The antitumor effects seen with the B16 melanoma and the CEA À tumors led us to believe that immune responses to other antigens expressed on MC38 tumors and potentially other tumor types, such as B16 melanoma, were induced by the CEA/TRICOM s.c. prime/i.t. boost vaccine regimen. It has been reported previously that MC38 tumors overexpress wild-type p53 (19) and an endogenous retroviral env epitope gp70 (21) . Reverse transcription-PCR analysis of MC38 parental cells, MC38-CEA + cells, and B16 tumor cells showed that these cells expressed substantial quantities of mRNA encoding p53 and gp70 (data not shown).
Analysis of Immune Responses Induced by CEA/ TRICOM Subcutaneous Prime/Intratumoral Boost Vaccination Therapy. To determine possible therapeutic mechanisms associated with the CEA/TRICOM s.c. prime/i.t. boost vaccine regimen, immunologic studies were conducted using MC38-CEA + tumor-transplanted CEA-transgenic mice. This (Fig. 2A) . Mice in group 2 were vaccinated with rV-CEA/TRICOM s.c. on day 8 and boosted s.c. with rF-CEA/TRICOM on days 15 and 22 (Fig.  2B) . Again, no significant antitumor activity was observed in this group. When mice were vaccinated with rV-CEA/TRICOM s.c. on day 8 and boosted i.t. with rF-CEA/TRICOM on days 15 and 22 (Fig. 2C) , tumor growth was significantly inhibited compared with that in the control ( Fig. 2C ; P = 0.0001); 50% (5 of 10) of the mice had regressing tumors, and the remaining mice (5 of 10) had growing tumors. To compare the immune responses between mice failing the CEA/TRICOM s.c./i.t. vaccine regimen and mice responding to the regimen, these mice were separated into two groups based on tumor volume (<200 versus >200 mm 3 on day 28) and designated vaccine responder (Fig. 2E ) and vaccine nonresponder (Fig. 2D) , respectively. These mice were sacrificed on day 29 and cells were used for in vitro immune assays.
To examine CEA-specific CD8 + T-cell responses, we tested splenic T cells from mice that had received the CEA/ TRICOM s.c./i.t. vaccine regimen for both CTL activity and cytokine production. Figure 3A Figure 3D depicts IFN-g production from CD8
+ T cells in response to CEA peptide. CD8 + T cells from vaccine responders produced the greatest levels of IFN-g (>3-fold greater than that noted from vaccine nonresponders). As shown in Fig. 3G , tumor necrosis factor-a production was also enhanced in the vaccine responders compared with that of vaccine nonresponders. There were no detectable levels of interleukin-2, interleukin-4, and interleukin-5 from CD8 + T cells in both vaccine responders and nonresponders. These results show that CEA-specific T-cell immune responses can be induced in a tumor-bearing self-antigen system and that the CD8 + T-cell responses specific for CEA show increased activity from mice showing antitumor activity in response to vaccine as opposed to mice failing the vaccine regimen. Next, CD4 + T cells were examined for proliferation in response to CEA protein (50 Ag/mL). CD4 + T cells from PBS-vaccinated control mice showed baseline proliferation in response to CEA protein. These responses were enhanced in mice showing antitumor activity following s.c./i.t. vaccination with CEA/ TRICOM (P = 0.0062 compared with control mice). The increased CEA-specific proliferation was also noted from mice failing to show antitumor activity to this vaccine regimen (P = 0.0015 compared with control mice).
Induction of an Antigenic Cascade in Mice after CEA/ TRICOM Subcutaneous Prime/Intratumoral Boost Vaccine Therapy. It has been reported that MC38-CEA + tumors overexpress wild-type p53 (19) and an endogenous retroviral env epitope gp70 (21) . To determine whether immune responses specific for these additional tumor antigens were induced in vaccinated mice, MHC class I -restricted p53 and gp70 peptides were used to evaluate CD8 + T-cell responses. We first tested CD8 + T-cell responses by CTL activity and cytokine production. Figure 3B depicts CTL activity of specific CD8 + T cells in response to p53 peptide (tumor target = EL-4 cells). CTLs specific for p53 were not detected from PBS-vaccinated control mice (o). When mice were vaccinated with the CEA/TRICOM s.c./i.t. regimen, this CTL activity was enhanced albeit weakly [P = 0.0005 versus vaccine nonresponders at 0.63:1 E:T ratio (E) and P = 0.0092 versus vaccine responders at 0.63:1 E:T ratio (n)]. IFN-g production from CD8
+ T cells in response to p53 peptide is shown in Fig. 3E . CD8 + T cells from vaccine responders produced IFN-g in response to p53 at 5-fold greater levels than that of vaccine nonresponders. As shown in Fig. 3H , tumor necrosis factor-a production was low in both vaccine responders and nonresponders.
In contrast to p53-specific responses, strong CD8 + T-cell responses specific for gp70 were seen in mice receiving the CEA/TRICOM s.c./i.t. vaccine regimen. Figure 3C depicts CTL activity of CD8 + T cells in response to gp70 peptide (tumor target = EL-4 cells). CD8 + T cells from the PBS control mice showed weak responses (o). This activity was significantly enhanced by vaccination with CEA/TRICOM vectors [P = 0.002 versus vaccine nonresponders at 0.63:1 E:T ratio (E) and P = 0.01 versus vaccine responders at 0.63:1 E:T ratio (n)]. The gp70-specific CTL activity was most significantly increased in the vaccine responder group (n) compared with that of vaccine nonresponders (P = 0.026 at 0.625:1 E:T ratio). On conversion of the data to lytic units, the LU 25 was <2.5 in the control (o), 14.3 in vaccine nonresponders (E), and 33.3 in vaccine responders (n).
IFN-g production from CD8
+ T cells in response to gp70 peptide is shown in Fig. 3F . All groups receiving CEA/ TRICOM s.c./i.t vaccine therapy showed increased IFN-g production compared with that seen in the control, but the increment was highest in vaccine responders. The amount was 2.7-fold greater than that in vaccine nonresponders. Moreover, as shown in Fig. 3I , tumor necrosis factor-a production in response to gp70 peptide was 3.5-fold greater in the vaccine responder group compared with that of vaccine nonresponders.
These results show that the CEA/TRICOM s.c./i.t. vaccine regimen could induce T-cell immune responses not only to CEA encoded in vectors but also to other antigens expressed on tumors but not encoded in vaccines. In addition, the gp70-specific CD8 + T-cell responses were much greater than that seen in response to other tumor antigens such as CEA or p53 (Fig. 3C, F, and I) . These results suggest that the success of the vaccine regimen could be influenced by induction of T-cell immune responses to other predominant antigens expressed on tumors, such as gp70.
Induction of gp70-Specific CTL Activity in Mice Vaccinated with the CEA/TRICOM Subcutaneous/Intratumoral Vaccine Regimen. CD8 + T-cell responses to gp70, not encoded in vaccines but expressed on tumors, were much greater than that seen in response to other tumor antigens (Fig.  3C, F, and I) . To further examine the potential role of gp70-specific CD8 + T cells in the antitumor response, studies were conducted to examine the CTL activity against MC38-CEA + tumor cells, which were implanted in vivo. We first tested CEAspecific CD8 + T cells obtained from mice vaccinated with the Splenic lymphocytes from CEA-transgenic mice depicted in Fig. 2A, D , and E were used 29 days after tumor t ransplant at ion (n = 5). A, CEA-specific CTL activity. B, p53-specific CTL activity. C, gp70-specific CTL activity. Tumor lysis was measured by 51 Cr release in supernatants. Control mice treated with PBS (o), nonresponders to CEA/TRICOM s.c./i.t. vaccine therapy (E), and responders to CEA/TRICOM s.c./i.t. vaccine therapy (n). D-F, antigen-specific IFNg production from CD8
+ T cells. G-I, antigen-specific tumor necrosis factor-a production from CD8 + T cells. Representative of three independent experiments.
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Research. Fig. 4A ; P = 0.003). There were no significant differences in EL-4 killing between nonresponders and responders to the s.c./i.t. vaccine regimen (P = 0.4349). In contrast, the CTL activity directed against MC38-CEA + tumors (without addition of CEA peptide) was significantly enhanced in responders than that in nonresponders (P = 0.0285), although CEA-specific CD8 + T cells from nonresponders significantly killed MC38-CEA + tumors compared with those from the control mice ( Fig.  4A ; P = 0.0237). In addition, when CEA À and gp70 À Mtag mammary tumor cells were used as a tumor targets, the CEAspecific CD8 + T cells did not show CTL activity (Fig. 4A) . We next tested gp70-specific CD8 + T cells obtained from mice vaccinated with the CEA/TRICOM s.c./i.t. regimen. Fig. 4 Induction of gp70-specific CTL responses in responders to the CEA/TRICOM s.c. prime/i.t. boost vaccine regimen. CEA-transgenic mice were vaccinated according to the same protocol described in Fig. 2 , and splenic lymphocytes were used 29 days after tumor transplantation (n = 4). A, CTL activity of CEA peptide-stimulated CTLs (CEACTLs). Splenic lymphocytes stimulated with CEA peptide for 6 days were used for 51 Cr release assay (E:T ratio = 40:1). B, CTL activity of gp70 peptide-stimulated CTLs (gp70-CTLs). Splenic lymphocytes stimulated with gp70 peptide for 6 days were used for 51 Cr release assay (E:T ratio = 40:1). C, CTL activity of gp70 peptide-induced CTLs from cured mice. CEA-transgenic mice were vaccinated s.c. with rV-CEA/ TRICOM on day 8 and then boosted s.c. with rF-CEA/TRICOM on days 15, 22, and 29. Cured mice after the therapy were used 88 days after tumor implantation. Splenic lymphocytes stimulated with gp70 peptide for 6 days were used for 51 Cr release assay (E:T ratio = 40:1). D, tumor challenge into cured mice. CEAtransgenic mice were vaccinated s.c. with rV-CEA/TRICOM on day 8 and then boosted s.c. with rF-CEA/TRI-COM on days 15, 22, and 29. Cured mice after the therapy were challenged with tumor cells (3 Â 10 5 ) 88 days after tumor implantation (n = 5, bold lines). As a control, age/sexmatched CEA-transgenic mice were implanted with same tumors (n = 3, thin lines ). Tumor volume was monitored twice a week.
These cells were stimulated with gp70 peptide for 6 days. Gp70-specific CD8 + T cells from vaccine responders showed greatest CTL activity ( Fig. 4B ; P = 0.0002 versus the control mice and P = 0.0005 versus vaccine nonresponders). In addition, these gp70-specific CD8 + T cells from vaccine responders strongly killed MC38-CEA + tumors ( Fig. 4B ; P = 0.0003 versus the control mice and P = 0.0004 versus vaccine nonresponders). The CTL activity of gp70-specific CD8 + T cells was much higher than that of CEA-specific CD8 + T cells in vaccine responders. When Mtag cells (gp70 À ) were used as a tumor target, CTL activity of gp70-specific CD8 + T cells was not observed (Fig. 4B) . To confirm that gp70-specific CTL from vaccinated mice could specifically recognize gp70 ) admixed with gp70 peptide were used as a target of gp70 peptide-induced CTLs, CTL activity was noted (Fig. 4C) . However, Mtag-CEA + cells (CEA + , gp70 -) or parental Mtag cells were not killed. This result shows that gp70-specific CTLs could specifically kill gp70 + tumors and that CTLs specific for additional tumor antigens could be induced in mice receiving the CEA/ TRICOM s.c./i.t. vaccine regimen.
We then examined the relevancy of gp70-specific T cells induced by the CEA/TRICOM s.c./i.t. vaccine regimen in vivo. When cured mice (vaccine responders) were challenged with MC38-CEA + tumors (CEA + , gp70 + ), tumor growth was strongly suppressed and all mice (5 of 5) were tumor free 16 days after tumor challenge (Fig. 4D) (Fig. 4D) . These results suggest that both CEA-specific and gp70-specific antitumor immune responses were induced by the CEA/ TRICOM s.c./i.t. vaccine therapy and could mediate antitumor activity. These results, taken together, suggest that CTL activity not only to CEA encoded in vaccine vectors but also to other tumor antigens not encoded in vaccines was responsible for successful vaccine therapy of established tumors and subsequent immune memory.
Detection of CD8 + T cells specific for CEA or gp70 were markedly increased in tumors of mice receiving the s.c./i.t. vaccine therapy compared with that seen in PBSvaccinated mice. The increment of both CEA-specific and gp70-specific T cells was significantly higher in vaccine responders than that in nonresponders (P = 0.0011 in CEAspecific CTLs and P = 0.0004 in gp70-specific CTLs). The level of gp70-specific CD8 + T-cell induction was higher than that of CEA-specific CD8 + T-cell induction in local tumor sites. Peripheral blood cells were analyzed for CEA-tetramer or gp70-tetramer binding (Fig. 4G) . Both CEA-specific and gp70-specific CD8 + T cells were significantly increased in peripheral blood of vaccine responders compared with that seen in the control mice and vaccine nonresponders (P = 0.0014) as well as local tumor sites. These results suggest that s. 
DISCUSSION
Here, we examined if direct overexpression of both signal-1 (CEA) and signal-2 (three costimulatory molecules; TRICOM) in tumor cells could potentiate antitumor activity. This was tested by using a vaccine regimen composed of first priming mice s.c. with rV-CEA/TRICOM and then boosting i.t. with rF-CEA/TRICOM, each admixed with rF-GM-CSF. Previously, we showed that both CEA and TRICOM were essential as transgenes in the prime vaccination vector (8, 9, 11, 25) . Here, it is shown that a s.c. prime and i.t. boost vaccination regimen with CEA/TRICOM vectors was effective in inhibiting the growth of CEA + tumors (Fig. 1) , and cured mice subsequently rejected a secondary challenge of MC38-CEA + tumors (Table 1) , showing long-term antitumor immunity. The s.c. prime/i.t. boost vaccination therapy with CEA/TRICOM vectors, however, was not effective in eliminating the growth of CEA À MC38 tumors (Fig. 1F ).
This result further shows the specificity of this therapy for CEA + tumors and highlights the requirement of CEA in the vaccine and in the tumors for optimal vaccine therapy. It should be pointed out that these studies used CEA-transgenic mice in which CEA is a self-antigen; these mice express CEA in normal gastrointestinal tissue and fetal tissue in a manner similar to that expressed in humans (12, 13) . These CEAtransgenic mice also contain CEA protein in sera at levels similar to that found in patients with advanced colorectal carcinoma (5-100 ng/mL).
When splenic T cells were tested for CEA-specific immune responses after the CEA/TRICOM s.c./i.t vaccine regimen, stronger CEA-specific CD8 + T-cell responses were noted in mice responding to the vaccine regimen than in mice failing the vaccine regimen (Figs. 3D and G (Table 1) . These results suggested that the tumor therapy could potentially be accompanied by the induction of immune responses to other antigens expressed on these tumors. Splenic T-cell immune responses to p53 and gp70, which were expressed on MC38-CEA + tumors but not encoded in vaccines, were observed in mice vaccinated with the CEA/TRICOM s.c./i.t regimen, and the CD8 + T-cell responses were most strongly induced in responders to the therapy (Figs. 3 and 4) . Moreover, CD8 + T-cell responses specific for gp70 were much greater than those specific for CEA or p53. Strikingly, the gp70-specific T-cell response level was correlative to the therapeutic efficacy, showing the greatest antitumor responses in responders to the s.c. prime/i.t. boost vaccination therapy.
Many CTLs specific for CEA and gp70 were seen to be infiltrating the tumors of mice that had received the CEA/ TRICOM s.c./i.t. therapy (Fig. 5) . Of note, these CTLs predominantly comprised CD8 + T-cell population in tumors and peripheral blood of vaccine responders. The increment of tumor antigen-specific CTLs was correlated to the therapeutic efficacy (i.e., vaccine nonresponders showed CTL increase in tumors and peripheral blood but to a lower degree than that observed in the vaccine responder group). Interestingly, the concentration of gp70-specific CTLs was greater than that of CEA-specific CTLs in local tumor sites of vaccine responders. These results indicate that the s.c. prime/i.t. boost vaccination with CEA/TRICOM vectors was essential for the initiation of antitumor effects, but the subsequent induction of antigen-specific immune responses by cross-priming led to efficient expansion and recruitment of gp70-specific CTLs into tumors, where these cells could play a crucial role in antitumor responses.
Meazza et al. reported that mice could reject parental TS/A tumors and CT-26 tumors challenged after rejection of MHC IItransfected TS/A tumors but could not reject gp70 À tumors (26). Rosato et al. showed that gp70-specific CTLs were generated in mice that rejected TS/A tumors transfected with costimulatory molecules or cytokines (27) . These studies suggested that gp70 is an influential CTL-immunodominant epitope that is commonly overexpressed on mouse tumors. Our findings confirm and extend these observations.
The results reported here of an ''antigen cascade'' support and extend previous results by several groups. Recently, Pilon et al. reported that HER-2/neu + tumor models cured after HER-2-encoding DNA vaccine therapy rejected HER-2/neu À tumors. It was hypothesized that this could have resulted from the broadening of epitope recognition (28) . Another study also suggested the epitope spreading induced by cross-priming, showing that CTLs specific for another epitope were seen in cured mice after immunotherapy using a P815-derived tumor peptide (29) . Such a phenomenon has also been reported in clinical studies. Cavacini et al. reported that after vaccination therapy of cancer patients with PSA + prostate tumors with rV/rF-PSA, sera were cross-reactive to multiple prostate tumor cell lines, including some that did not express prostate-specific antigen (30) . Butterfield et al. observed that spreading of immune reactivity was induced only in melanoma patients with a complete response after i.t. vaccination therapy with MART1-pulsed dendritic cells (31) . These studies support our hypothesis that the breadth and magnitude of antitumor immune cascades to multiple antigens expressed on tumors could be critical in the therapy of established tumors.
Taken together, these studies show that the TAA (in this case, CEA) must be present in both the vaccine and the tumor to initiate the antitumor response. Subsequent cross-priming of an antigen cascade could then be initiated/potentiated by additional antigens (in this case, p53 and gp70) expressed on the tumors. The potentiation of the antitumor response that led to complete tumor regression seemed to be related to an immune response generated to a predominant antigen (gp70) not encoded in the vaccine. These studies thus have important implications in the analysis of a given patient's immune response in vaccine clinical trials. To this point, the vast majority of studies have followed only the generation of T-cell responses directed against the TAA in the vaccine. The studies reported here provide further evidence that the magnitude and/ or breadth of an antigen cascade (distinct from that antigen in vaccines) may determine the effectiveness of the antitumor therapy.
